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Abstract
It was recently revealed that gut microbiota promote amyloid-beta (Aβ) burden in mouse models of Alzheimer’s
disease (AD). However, the underlying mechanisms when using either germ-free (GF) housing conditions or
treatments with antibiotics (ABX) remained unknown. In this study, we show that GF and ABX-treated 5x familial AD
(5xFAD) mice developed attenuated hippocampal Aβ pathology and associated neuronal loss, and thereby delayed
disease-related memory deficits. While Aβ production remained unaffected in both GF and ABX-treated 5xFAD
mice, we noticed in GF 5xFAD mice enhanced microglial Aβ uptake at early stages of the disease compared to
ABX-treated 5xFAD mice. Furthermore, RNA-sequencing of hippocampal microglia from SPF, GF and ABX-treated
5xFAD mice revealed distinct microbiota-dependent gene expression profiles associated with phagocytosis and
altered microglial activation states. Taken together, we observed that constitutive or induced microbiota
modulation in 5xFAD mice differentially controls microglial Aβ clearance mechanisms preventing
neurodegeneration and cognitive deficits.
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Introduction
Alzheimer’s disease (AD) is the most common neurode-
generative disease and cause of dementia worldwide [9].
The progressive loss of neurons causes symptoms such
as memory loss and cognitive decline. Despite enormous
efforts in AD research, the etiology of the frequent spor-
adic form of AD remains largely unknown [47]. The her-
editary familial form of AD accounts only for less than
5% of all cases of AD and typically has a much earlier
onset [51]. The main hallmarks of this incurable disease
in the brain are extracellular amyloid-beta (Aβ) deposi-
tions and intracellular neurofibrillary tangles. The early
aggregation and cerebral deposition of Aβ is suggested
to take place decades before the first symptoms appear
[48], and Aβ depositions mainly drive the development
and progression of AD [53]. In the central nervous sys-
tem (CNS) microglia represent the main innate immune
cells, and in contrast to other tissue macrophages have a
unique solely yolk-sac origin [17, 24, 46]. While they are
essential for maintaining tissue homeostasis during
physiological conditions [25], microglia continuously
survey their microenvironment, react to pathological
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stimuli and are involved in virtually all CNS diseases in-
cluding AD pathogenesis [39, 44]. Recent genome-wide
association studies (GWAS) showed that genes mainly
or exclusively expressed by microglia, including comple-
ment receptors, or triggering receptor expressed on
myeloid cells-2 (TREM2) are associated with increased
risk of developing AD [28]. Microglia sense Aβ by sev-
eral receptors (i.e. TREM2) resulting in microglial activa-
tion, accumulation around Aβ plaques and production
of potential neurotoxic proinflammatory cytokines [44,
59]. As the professional phagocytes of the CNS, micro-
glia play a crucial role in the removal of Aβ aggregates
[44]. Interestingly, microglia in Trem2-deficient 5xFAD
mice incorporated less Aβ than microglia from Trem2-
expressing 5xFAD mice [60].
Growing body of evidence highlight a considerable in-
fluence of gut microbes on the host’s health [21].
Microbiota-derived molecules, such as short-chain fatty
acids (SCFAs), have been shown to contribute to host’s
physiology and boost immune functions [21]. We have
previously demonstrated that the maturation and func-
tion of microglia were highly affected by host gut mi-
crobes [12]. In mice born and raised under germ-free
(GF) conditions, microglia displayed an immature
homeostatic phenotype defined by altered gene expres-
sion, increased numbers, and hyper-ramified morph-
ology. In addition, they displayed compromised immune
response upon acute challenge with bacterial molecules
and virus infection [12]. Notably, temporal eradication
of gut bacteria by antibiotic treatment (ABX) in former
colonized adult SPF mice induced a comparable micro-
glial phenotype to GF mice, arguing that constant signals
from gut bacteria are necessary for proper microglial
homeostasis und function [12]. Remarkably, the patho-
physiology of several CNS diseases including AD was re-
cently linked to host microbiota [14]. Harach and
colleagues uncovered that AD pathology is diminished
in the double transgenic APPPS1 AD mouse model
under GF housing conditions compared to colonized
controls [18]. Furthermore, postnatal long-term micro-
biota manipulation by ABX reduced Aβ burden in
APPSWE/PS1ΔE9 mice compared to non-treated controls
[34]. However, the precise role of microglia, the involved
cellular mechanism, the impact on cognitive function,
and whether the production or degradation of Aβ is af-
fected, remained unclear.
In order to gain mechanistic insights, we characterized
the Aβ-associated pathology and related hippocampus-
associated behavior at an early and progressed stage of
the disease using 5x familial AD (5xFAD) mice bred
under both GF and specific pathogen free (SPF) condi-
tions and induced gut bacteria depletion by ABX in a
third cohort. Additionally, we thoroughly investigated
the influence of the constant and induced depletion of
gut bacteria on microglia-mediated effects during Aβ
pathology. We revealed that constitutive absence of gut
microbiota in GF 5xFAD mice increased the microglial
uptake of Aβ deposits in the hippocampus, resulting in
decreased Aβ burden, associated neuronal loss and
retained hippocampus-associated memory function,
without affecting the production of Aβ. While ABX-
induced acute depletion of gut bacteria resulted in simi-
lar decrease of Aβ depositions, this effect was not attrib-
uted to microglial Aβ phagocytosis.
Materials and methods
Mice
As a mouse model of Alzheimer’s disease we used het-
erozygous male 5xFAD transgenic mice and non-
transgenic littermates (4 and 10 months of age) on a
C57BL/6 J background co-expressing human
APPK670N/M671L (Sw) + I716V (Fl) + V717I(Lo) and PS1M146L +
L286V under the control of the neuron-specific Thy-1
promoter [38]. Mice were housed under specific
pathogen-free (SPF) conditions under a 12-h light, 12-h
dark cycle with food and water ad libitum at CEMT
(Freiburg, Germany). GF 5xFAD mice were generated
via embryo transfer by Kathleen McCoy. GF heterozy-
gous 5xFAD and WT littermates were obtained from the
Clean Mouse Facility (Bern, Switzerland). In order to de-
plete microbiota, mice were treated orally via drinking
water with a mixture of antibiotics (ABX), containing 1
mg/ml vancomycin (Hexal), 1 mg/ml cefoxitin (Santa
Cruz Biotechnology), 1 mg/ml gentamicin (Sigma-Al-
drich) and 1mg/ml metronidazol (Sigma-Aldrich) for 2
months as described previously [12]. All animal experi-
ments were approved by the Ministry for Nature, Envir-
onment and Consumers` Protection of the state of
Baden-Württemberg and were performed in accordance
to the respective national, federal, and institutional regu-
lations (G19–02 and X16-04A).
Histology & Immunofluorescence
Mice were deeply anesthetized by intraperitoneal injec-
tion of a mixture of ketamine (100 mg/kg body weight)
and xylazine (10 mg per kg body weight) and transcar-
dially perfused with ice-cold 1xPBS. Collected brains
were post-fixed in 4% PFA for 24 h. One hemisphere
was cryopreserved in 30% sucrose for 48 h, whereas the
other hemisphere was paraffin embedded. Cryopreserved
brains were frozen on dry ice and cut into 25 μm thick
coronal serial sections on a sliding microtome
(SM2000R, Leica Biosystems) and collected in 5% gly-
cerol. As described previously [66], every tenth brain
sections containing hippocampus from rostral to caudal
were immunolabeled free-floating by incubating with
anti-Iba1 antibody (rabbit, 1:500, Wako) and anti-Clec7a
(1:30, Invivo Gen) for 24 h at 4 °C. Subsequently,
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sections were incubated with Alexa-Fluor-488 and 647-
conjugated secondary antibody (1:500, Life technologies)
for 24 h at 4 °C. Compact Aβ plaques were stained with
2 μM thiazine red (TR) (Sigma-Aldrich), a fluorescent
congo red derivate, for 5 min at room temperature (RT).
Finally, nuclei were stained with DAPI (4′,6-diamidin-2-
phenylindol, 1:10000) for 10 min at RT. Additional series
of brain sections were immunolabeled to visualize com-
pact Aβ-plaques, as well as 1–16 Aβ precursor forms by
using anti-6E10 antibody (1:1000, Biolegend) and anti-
Iba1 antibody (1:500, Wako) at 4 °C for 24 h, followed by
incubation with corresponding conjugated secondary
antibodies Alexa-Fluor-568 and 488 (1:500, Life tech-
nologies) for 24 h at 4 °C. DAPI was used as a nuclear
stain for 10 min at RT. Aβ-plaque load and density of
Iba1-immunoreactive cells were quantified throughout
the entire hippocampus. In total 10 to 12 sections were
analyzed per mouse.
Paraffin-embedded brains were cut sagittal into 3 μm
thin sections and immunofluorescence labeling was per-
formed by using following primary antibodies: anti-
NeuN (1:200, Abcam), anti-Iba1 (1:500, Synaptic Sys-
tem), anti-P2ry12 (1:200, AnaSpec) and anti-ApoE (1:50,
Merck), upon antigen retrieval (pH 6.0 citrate) at 4 °C
for 24 h. Subsequently, respective conjugated secondary
antibodies Alexa-Fluor 647 or 488 (1:500, Life technolo-
gies) were used for 2 h at RT. Aβ plaques were visualized
by TR for 5 min at RT. Nuclei were stained with DAPI
(1:10000) for 10 min at RT. Fluorescence images were
taken with BZ-9000 Biorevo microscope (Keyence).
Sections were analyzed by using BZ-II Analyzer Software
(Keyence). Confocal images were taken with Olympus
Fluoview FV 1000 confocal laser scanning microscope
(Olympus).
Behavior analysis
Spatial working memory was tested using the continuous
spontaneous alternation task in a T-maze as described
previously [10, 49]. In short, animals were set into the
base of a T-maze and forced to explore one of the T-
maze arms until it returned to the base arm. Subse-
quently, the blocked arm was opened, and the animal
could explore the maze. Once one arm of the T-maze
was entered, the other arm was blocked until the animal
returned to the base arm. Then, the exit of the base arm
was blocked for 5 s and the animal explored the maze
again. The experiment was stopped after 14 free choice
arm entries. Arm entries were scored as alternations if
an animal chose the opposing arm compared to the arm
visited immediately prior to the scored instance. Repeti-
tive arm entries were scored as entering the same arm
for the third or more consecutive time. The total time
after 14 free choice arm entries was recorded.
The Novel Object Recognition (NOR) task was applied
to evaluate recognition memory as published previously
[2, 37]. During the habituation phase, each mouse could
explore two similar objects within a total exploration
time of 20 s. We commenced the testing phase 6 h after
the habituation phase. During the testing session, each
mouse could explore a familiar object and a novel object
of different shape and texture. The position of the novel
object and the familiar object was randomized between
each mouse. The time spent by each mouse to explore
the novel object and the familiar object was noted. The
experiment was stopped when the total exploration time
reached 20 s. The time spent by each mouse to explore
the novel object and the familiar object, as well as the
total time for paradigm completion during the testing
phase was recorded.
Ex vivo microglia isolation and flow cytometry
Hippocampi were collected and microglia were enriched
by using density gradient separation and were prepared
as described previously [12, 65]. The cell suspension was
then incubated with Fc receptor blocking antibody
CD16/CD32 (1:200, BD Bioscience) and Fixable Viability
Dye eFluor® 780 (1:1000, eBioscience) for 10 min at 4 °C.
Subsequently, the following antibodies were used: anti-
CD11b (1:200, clone M1/70, Biolegend), anti-CD45 (1:200,
clone 30-F11, BioLegend), anti-CD11c (1:100, clone N418,
Biolengend) and for lineage exclusion by a dump gate anti-
CD3 (1:300, clone 17A2, Biolegend), anti-CD19 (1:300,
clone 6D5, Biolegend), anti-CD45R (1:300, clone RA3-6B2,
BD Bioscience), anti-Ly6C (1:300, clone AL-21, BD
Bioscience) and anti-Ly6G (1:300, clone 1A8, BD
Bioscience) and incubated for 30 min at 4 °C.
Ex vivo Aβ phagocytosis assay
Mice were injected intraperitoneally with methoxy-X-O4
(Tocris) (10 mg/kg bodyweight), a fluorescent congo red
derivate, in a DMSO/PBS mixture. After 3 h, hippocampi
were collected and microglial cells were assessed as de-
scribed previously [65]. Percentage of methoxy-XO-4
positive microglia were determined by flow cytometry
using a FACS Canto II (BD Bioscience) and analyzed
with FlowJo software (Tree Star).
Microbial profiling of caecal contents
DNA extraction, 16S rRNA sequencing and computation
analysis of caecal contents from 4months old SPF and
ABX-treated 5xFAD mice and respective WT controls
was performed as described previously [62] with slight
modifications. 12 SPF and 16 ABX-treated 5xFAD mice,
as well as 15 SPF and 14 ABX-treated WT mice were
analyzed. In brief, caecal contents were collected in 2 ml
microfuge tubes and stored at − 80 °C prior to DNA ex-
traction. Total DNA was isolated from samples using
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the QIAamp DNA stool kit (Qiagen) according to
the modified manufacturer’s instructions. Afterwards,
100 - 400 ng of DNA samples were subjected to ampli-
fication of V5/V6 region of bacterial 16S rRNA. Bacteria-
specific primers (forward 5′ CCATCTCATCCCTGCG
TGTCTCCGACTCAGC barcode ATTAGATACC
CYGGTAGTCC 3′ and reverse 5′ CCTCTCTATG
GGCAGTCGGTGATACGAGCTGACGACARCCATG-3′)
were used. Amplicon sequencing was performed using the
Ion PGM™ Sequencing 400 Kit and Ion 316™ Chip V2 within
the Ion PGM™ System (Thermo Fisher). Fastq sequencing
files were first loaded into the QIIME 1.9.1 pipeline
[8], using custom analysis scripts for analysis on the
UBELIX Linux cluster of the University of Bern [62].
The biom file and mapping file were used for statistical
analyses and data visualization in the R with package
phyloseq. The α-diversity (Observed OTUs, Simpson
and Shannon index), β-diversity (Bray-Curtis genus-
level community dissimilarities), and statistical ana-
lysis of clustering using Mann-Whitney U tests for
alpha diversity and Adonis (PERMANOVA) for beta
diversity to confirm that the strength and statistical
significance of groups in the same distance metrics in
phyloseq using R [33]. The multivariate analysis by
linear models (MaAsLin) R package were used to find
associations between metadata and microbial community
abundance [36]. Plots were generated with ggplot2
using phyloseq object.
Quantification of bacterial load by flow cytometry
Fecal samples were collected from SPF, GF and ABX-
treated mice and weighted, immediately homogenized
in ice-cold 1xPBS and filtered through 50 μm Cell-
Trics filters (Sysmex). A fraction of the filtrates was
diluted 1:20 in 1xPBS and centrifuged for 5 min at
3000 g at 4 °C. Subsequently, supernatant was aspi-
rated and Syto9 (1:1000 in PBS, Thermo Fisher), a
dye to identify gram+ and gram- bacteria was added
for 10 min at 4 °C. DAPI (1:1000) was used for dead
cell exclusion and the percentage of live bacteria was
recorded by using flow cytometry. Flow cytometry cell
counting beads (1:20, Thermo Fisher) were added to
quantify absolute number of live bacteria per mg fecal
sample.
RNA-sequencing
Total RNA was extracted from FACS sorted viable
CD11b+CD45lowDUMP− hippocampal microglia cells
using the ARCTURUS® PicoPure® RNA Isolation Kit
(Thermo Fisher) according to manufacturer’s protocol.
The SMARTer Ultra Low Input RNA Kit for Sequencing
v4 (Clontech Laboratories, Inc., Mountain View, CA,
USA) was used to generate first strand cDNA from 300
pg total-RNA. Double stranded cDNA was amplified by
LD PCR (13 cycles) and purified via magnetic bead
clean-up. Library preparation was carried out as de-
scribed in the Illumina Nextera XT Sample Preparation
Guide (Illumina, Inc., San Diego, CA, USA). 150 pg of in-
put cDNA were tagmented (tagged and fragmented) by
the Nextera XT transposome. The products were purified
and amplified via a limited-cycle PCR program to generate
multiplexed sequencing libraries. For the PCR step 1:5 di-
lutions of index 1 (i7) and index 2 (i5) primers were used.
The libraries were quantified using the KAPA SYBR FAST
ABI Prism Library Quantification Kit (Kapa Biosystems,
Inc., Woburn, MA, USA). Equimolar amounts of each li-
brary were pooled, and the pools were used for cluster
generation on the cBot with the Illumina TruSeq SR Clus-
ter Kit v3. The sequencing run was performed on a HiSeq
1000 instrument controlled by the HiSeq Control Soft-
ware (HCS) 2.2.38, using the indexed, 50 cycles single-
read (SR) protocol and the TruSeq SBS v3 Reagents ac-
cording to the Illumina HiSeq 1000 System User Guide.
Image analysis and base calling were done by the Real
Time Analysis Software (RTA) 1.18.61. The resulting .bcl
files were converted into fastq files with the CASAVA
Software 1.8.2. Library preparation and RNAseq were per-
formed at the Genomics Core Facility “KFB - Center of
Excellence for Fluorescent Bioanalytics” (University of Re-
gensburg, Regensburg, Germany; www.kfb-regensburg.de).
Fastq files were quality controlled using FastQC [1]
and reads were mapped to the GRCm38 mouse genome
using the Star aligner [11]. Read counts were obtained
using the featureCounts program [30] in conjunction
with the Gencode transcriptome version M21 [15]. Dif-
ferential gene expression analysis was performed using
the limma/voomWithQualityWeights pipeline in R [29,
31]. Venn diagram was generated by using previously
published tools [19]. Heatmaps were generated using the
package pheatmap [40]. Pathway analysis was performed
using Ingenuity Pathway Analysis (IPA, QIAGEN).
Elisa
Quantification of soluble and insoluble Aβ40 and 42
species in hippocampal homogenates were quantified by
performing enzyme-linked immunosorbent assay as de-
scribed previously [66]. Briefly, hippocampi were har-
vested and homogenized (10% w/v) in 1xPBS containing
protease inhibitor and sequentially extracted with PBS
(soluble fraction), PBS + 0.1% Triton X-100 (membrane
bound fraction) and finally with 8M guanidine hydro-
chloride solution (insoluble fraction). Protein concentra-
tion in each fraction was measured by using Bradford
assay (Carl Roth) and ELISA was performed using Hu-
man Aβ42 ultrasensitive ELISA kit and Human Aβ40/
Aβ42 ELISA kits (Invitrogen) according to manufac-
turer’s protocols.
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Fig. 1 (See legend on next page.)
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Western blot analysis
Hippocampi were harvested and homogenized in
RIPA buffer (25 mM Tris-HCl, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
protease inhibitor, pH 7.5) to extract total protein.
Total protein concentration was determined by using
Bradford assay (Carl Roth). Samples were separated
by 4–12% NuPAGE Bis-tris mini gels (Invitrogen) and
immunoblotted using antibodies against APP and
CTFs (1:3000, Sigma), BACE1, ADAM10 (1:1000, Cell
Signaling Technology), Nicastrin, PEN2, Presenilin 1
and 2 (PS1, PS2) (1:1000, γ Secretase Antibody Sam-
pler Kit, Cell Signaling Technology) and anti-Aβ
(6E10, 1:3000, Biolegend) for 24 h at 4 °C. Anti-β-
actin-HRP (1:5000, Abcam) was used as loading con-
trol. Immunoblots were incubated with corresponding
HRP-linked secondary antibodies for 1 h at RT and
visualized by using SuperSignal™ West Femto Max-
imum Sensitivity Substrate (Thermo Fisher).
Statistical analysis
Statistical analysis was performed using GraphPad
Prism (GraphPad Software, Version 5.0, La Jolla,
USA). All data were tested for normality applying the
Shapiro-Wilk normality test. If normality was given,
either an unpaired t test, one-way ANOVA followed
by Tukey’s post-hoc comparison test or two-way
ANOVA followed by Bonferroni’s compression was
applied respectively. Differences were considered sig-
nificant when P value < 0.05. To obtain unbiased data,
experimental mice were all processed together. Cell
quantifications were performed blinded by two scien-
tists independently and separately.
Results
Absence of gut microbiota ameliorates hippocampal Aβ
burden of 5xFAD mice
To investigate whether gut microbiota is detrimental or
beneficial during neurodegeneration, we took advantage
of the 5xFAD mouse model that recapitulates major fea-
tures of the Aβ pathology [38]. In 5xFAD mice, Aβ pla-
ques start to appear at around 2months of age [38]. In
order to evaluate the modulation of an early phase of
the disease in 5xFAD mice by gut microbiota, we first
compared 4 months old GF 5xFAD to colonized (specific
pathogen free, SPF) 5xFAD mice. Additionally, we
treated SPF 5xFAD mice orally with ABX for 2months
prior to analyze at an age of 4 months.
GF-housed and ABX-treated mice displayed enlarged
caeca with dark-colored caecal contents and incremen-
ted caecal weights compared to SPF controls, as previ-
ously described [12] (Suppl. Fig. 1A-C). To confirm the
successful reduction of gut bacteria after ABX applica-
tion, we quantified the number of live bacteria in fecal
samples by flow cytometry (Suppl. Fig. 1D - F). In line,
we observed a significant reduction in species richness
in ABX-treated 5xFAD mice and wild-type (WT) litter-
mates (Suppl. Fig. 1G & H). In contrast to a recent report
[5], we did not detect substantial differences in species
richness (q-value < 0.05) in caecal contents of SPF 5xFAD
and non-transgenic littermates (Suppl. Fig. 1I - K and
Additional files 6 and 7). First, to analyze the amount of
Aβ depositions by histopathological assessment in hippo-
campi of 4 months old SPF, GF and ABX-treated 5xFAD
mice, we took advantage of the fluorescent congo red
derivate thiazine red (TR) which visualizes compact Aβ
depositions (Fig. 1A). In line with previous observations in
other AD mouse models [18, 34], the amount of TR+
(See figure on previous page.)
Fig. 1 Absence of host microbiota reduces hippocampal Aβ depositions of 5xFAD mice. (a) Representative fluorescence images of thiazine red+
(TR; red) compact Aβ plaques in the hippocampus of 4 months old SPF, GF and ABX-treated 5xFAD mice. Nuclei were stained with DAPI (blue).
Overview of hippocampus and magnification of subiculum (dashed line) are shown. Scale bars represent 300 μm (overview) and 50 μm (insert).
(b) Quantification of the number of TR+ Aβ-plaques per mm2, (c) percentage of TR+ area and (d) average TR+ plaque size (μm2) in coronal
hippocampal sections. Each symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by one-
way ANOVA followed by Tukey’s post-hoc comparison test (*P < 0.05, **P < 0.01, ***P < 0.001). Data are representative of four independent
experiments. Enzyme-linked immunosorbent assay (ELISA) for (e) insoluble Aβ42, (f) insoluble Aβ40, (g) soluble Aβ42 and (h) soluble Aβ40
fractions of hippocampal brain extracts from 4months old SPF, GF and ABX-treated 5xFAD mice. Each symbol represents one mouse. Data are
presented as mean ± s.e.m. Significant differences were determined by one-way ANOVA followed by Tukey’s post-hoc comparison test (**P < 0.01,
***P < 0.001). Data are representative of two independent experiments. (i) Representative immunoblots of hippocampal brain homogenates from
4months old SPF, GF and ABX-treated 5xFAD mice against human full-length amyloid precursor protein (APP-FL), C-terminal fragment (CTF) α,
CTF-β, β-site of APP cleaving enzyme (BACE) 1, A Disintegrin And Metalloproteinase (ADAM10), γ-secretase complex (Nicastrin, presenilin
enhancer (PEN) 2, Presenilin (PS) 1, PS2) and Aβ (6E10). β-Actin was used as loading control. Each lane represents one mouse. Quantification of (j)
APP-FL, (k), CTF-β, (l) CTF-α, (m) BACE1, (n) ADAM10, (o) PS1, (p) PS2, (q) PEN2, (r) Nicastrin, and (s) Aβ protein levels normalized to β-Actin are
shown. Each symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by one-way ANOVA
followed by Tukey’s post-hoc comparison test (*P < 0.05). Data are representative of two independent experiments. (t) Representative
fluorescence images of TR+ compact Aβ plaques in the hippocampus of 10 months old 5xFAD mice. Nuclei were stained with DAPI (blue).
Overview of hippocampus and magnification of subiculum (dashed line) are shown. Scale bars represent 300 μm (overview) and 50 μm (insert).
(u) Quantification of the number of TR+ Aβ-plaques per area (mm2), (v) percentage of TR+ area and (w) average of TR+ plaque size (μm2). Each
symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by one-way ANOVA followed by
Tukey’s post-hoc comparison test (**P < 0.01, ***P < 0.001). Data are representative of four independent experiments
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compact plaques was diminished in hippocampi of GF
and ABX-treated 5xFAD mice compared to SPF 5xFAD
controls (Fig. 1A - C). Additional immunofluorescence
labelling with the 6E10 antibody, targeting compact and
diffuse Aβ, showed similar results (Suppl. Fig. 2A - C). Of
note, we observed significantly smaller plaques under GF
conditions compared to SPF and ABX-treated 5xFAD
mice (Fig. 1D & Suppl. Fig. 2D). In accordance, both insol-
uble Aβ42 and Aβ40 (Fig. 1E & F, Suppl. Fig. 2E) as well
as soluble Aβ42 and Aβ40 fractions (Fig. 1G & H, Suppl.
Fig. 2F) were significantly decreased in hippocampal brain
homogenates of GF and ABX 5xFAD mice when
compared to SPF 5xFAD controls. To assess a potential
effect of gut microbiota on the processing of the amyloid
precursor protein (APP), we measured APP and its
C-terminal fragments (CTF-α, CTF-β) as well as
secretases involved in APP-processing, including β-
secretase (β-site of APP cleaving enzyme, ΒΑCΕ1), A
Disintegrin And Metalloproteinase (ADAM)10 and com-
ponents of the γ-secretase complex (Nicastrin, PEN2, Pre-
senilin1, Presenilin 2) in hippocampal tissue extracts by
immunoblotting and detected no alterations (Fig. 1I – R).
Consistent with the ELISA results, western blot ana-
lysis also demonstrated significantly lower Aβ levels
in both GF and ABX 5xFAD mice compared to SPF
5xFAD animals (Fig. 1S).
Next, we asked whether the Αβ accumulation was
modulated at a later progressed stage of AD pathology
by either constant or induced microbial absence. There-
fore, we investigated SPF and GF housed 5xFAD mice at
an age of 10 months. Additionally, ABX treatment of
SPF 5xFAD mice was started 2 months prior to analysis
at an age of 10 months. Compared to the 4 months old
SPF 5xFAD mice, we noticed a robust increase of TR+
Aβ depositions in 10 months old SPF 5xFAD animals,
whereas GF and ABX-treated 5xFAD mice developed
significantly less and smaller Aβ plaques (Fig. 1T - W).
Consequently, both insoluble and soluble Aβ42 and
Aβ40 fractions were decreased in hippocampi of GF
and ABX 5xFAD mice compared to SPF 5xFAD
controls (Suppl. Fig. 2G - K). APP processing also
showed no significant alterations in the aged GF
5xFAD mice (Suppl. Fig. 2L – U). Altered Aβ load
was additionally detected by immunoblot and 6E10
immunofluorescence labelling (Suppl. Fig. 2V – Z),
indicating a possible modulation of Aβ pathology even at
later stages of the disease. In sum, our findings highlight a
disease-promoting role of gut bacteria during Aβ-
mediated neurodegeneration, whereas modulation thereof
might improve the disease course.
Gut bacteria influence memory function of 5xFAD mice
To elucidate whether the reduced Aβ plaque burden in
10months old GF and ABX 5xFAD mice compared to
the steadily colonized SPF 5xFAD controls is affecting
cognitive function, we first examined spatial working
memory in the T-maze paradigm. As expected, SPF
5xFAD mice showed decreased percentage of arm alterna-
tion and more re-entries into the same arm of the T-maze
(Fig. 2A - C) compared to age-matched SPF WT litter-
mates. Both GF housing (Fig. 2A – C & Suppl. Fig. 3A)
and oral ABX application (Fig. 2D – F & Suppl. Fig. 3B)
partially rescued this phenotype in 5xFAD mice, whereas
the SPF, GF and ABX WT controls showed no behavioral
abnormalities. Furthermore, when tested in the novel
object recognition (NOR) task, GF 5xFAD (Fig. 2G - I) as
well as ABX-treated 5xFAD mice (Fig. 2J - L) spent
significantly more time exploring the novel object
compared to SPF 5xFAD mice, suggesting partially
protected learning and recognition memory. Import-
antly, impairment of spatial and recognition memory
in colonized SPF 5xFAD mice was accompanied by
prominent neuronal loss in the subiculum (sub) as
well as in the cornu ammonis (CA) 1 region, while
we did not observe significant neuronal loss in the
CA3 and dentate gyrus (DG) (Fig. 2M – Q). Micro-
biota manipulation at early disease stages in 4months old
5xFAD mice did not yet affect markedly hippocampus-
associated memory functions (Suppl. Fig. 3C - P) or
neuronal survival (Suppl. Fig. 4Q & R). Collectively,
our data show a detrimental role of microbiota in the
5xFAD mouse model worsening spatial and recognition
(See figure on previous page.)
Fig. 2 Restored memory deficits in 5xFAD mice lacking microbes. (a-c) T-maze test performance of 10 months old SPF and GF 5xFAD mice, as
well as aged-matched WT controls or (d-f) of 10 months old SPF and ABX 5xFAD mice, as well as WT controls. (g-i) Novel object recognition test
(NOR) of 10 months old SPF and GF 5xFAD mice, as well as age-matched WT controls or (j-l) of 10 months old SPF and ABX 5xFAD mice, as well
as respective WT controls. Each symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by
two-way ANOVA followed by Bonferroni’s post-hoc comparison test (*P < 0.05, **P < 0.01, ***P < 0.001). Data are representative of three
independent experiments. (m) Representative immunofluorescence images of NeuN+ neurons (green) and TR+ (red) compact Aβ plaques in the
subiculum (Sub), cornu ammonis (CA) 1, CA3 and dentate gyrus (DG) of the hippocampus of 10 months old SPF, GF and ABX-treated 5xFAD
mice. Nuclei were stained with DAPI (blue). Overview of hippocampus and magnifications of subiculum, CA1, CA3 and DG (dashed lines) are
shown. Scale bars represent 200 μm (overview) and 50 μm (inserts). Quantification of the number of NeuN+ neurons per mm2 in the subiculum
(n), CA1 (o), CA3 (p) and DG (q) of sagittal hippocampal sections from SPF, GF and ABX-treated 5xFAD and age-matched WT mice. Each symbol
represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by two-way ANOVA followed by Bonferroni’s
post-hoc comparison test (**P < 0.01, ***P < 0.001). Data are representative of two independent experiments
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memory along with reduced neuronal numbers in the
hippocampus.
Constitutive lack of microbiota augments microglial
uptake of Aβ debris
We previously demonstrated that microglial features
are essentially steered by the host microbiota [12].
In addition, it is widely accepted that microglia crit-
ically contribute to AD progression [44]. Following
our own and previous observations [18, 34] showing
that microbiota have a negative impact on AD path-
ology in different mouse models of AD, we aimed to
clarify the cellular mechanism resulting in decreased
Aβ pathology under GF or ABX conditions. To
examine the functional role of microglia in 4 months
old SPF, GF and ABX-treated 5xFAD mice, we first
quantified Iba1+ parenchymal microglia numbers in
the hippocampi and compared them to the respect-
ive WT controls (Fig. 3A & B, Suppl. Fig. 4A).
5xFAD mice housed under GF conditions displayed
an higher microglial density in the hippocampal tis-
sue compared to SPF 5xFAD mice, while ABX treat-
ment did neither affect microglia density in 5xFAD
mice nor WT mice in line with previous findings
[12, 54] (Fig. 3A & B, Suppl. Fig. 4A). Next, we ex-
amined in detail microglia located in a close proxim-
ity (< 10 μm) to TR+ Aβ plaques. We noticed
significantly more TR+ Aβ plaque-associated Iba1+
microglia in GF 5xFAD mice (Fig. 3A & C), whereas
SPF and ABX-treated 5xFAD mice showed less accu-
mulation of Iba1+ microglia around TR+ Aβ plaques.
Similar results were found by using 6E10 immuno-
fluorescence for compact and diffuse Aβ debris
(Suppl. Fig. 4B & C). It has been suggested that plaque-
associated microglia are critical in preventing senile Aβ
plaque formation in AD mouse models, for example by in-
creased phagocytosis [23, 27]. Hence, we investigated
whether permanent absence or induced microbiota deple-
tion alters microglial phagocytosis by performing ex vivo
flow cytometric based analysis of Aβ uptake using
methoxy-X-O4 staining as described before [65] (Fig. 3D
& E, Suppl. Fig. 5A). In line with the increased Aβ plaque-
associated Iba1+ microglia numbers in GF 5xFAD mice,
we observed higher percentage of methoxy-X-O4+ micro-
glial cells under GF conditions (Fig. 3D - F), indicating
higher Aβ uptake. Notably, 2 months supplementation of
ABX via drinking water did not affect the percentage of
methoxy-X-O4+ microglial cells which was comparable to
SPF levels (Fig. 3D – F). These findings underline that
ABX-induced microbiota reduction in 5xFAD mice is not
sufficient to modulate Aβ uptake by microglia as observed
in GF 5xFAD animals.
Permanent absence of microbes alters microglial gene
profile in GF 5xFAD mice
To examine the effector functions of microglia in 5xFAD
mice lacking microbes in more detail, we FACS-isolated
hippocampal microglia from 4months old SPF, GF and
ABX 5xFAD mice and the respective age-matched WT
controls and analyzed genome-wide mRNA expression
profiles by RNA-sequencing (seq) (Fig. 4A & B). In gen-
eral, 680 genes were similarly modulated under SPF,
ABX and GF conditions in 5xFAD mice compared with
non-transgenic WT controls (Fig. 4A, Additional file 8).
Notably, microglia from SPF 5xFAD animals regulated
1006 individual genes, whereas microglia from GF
5xFAD mice displayed specific expression changes in
1185 genes and microglia in ABX-treated 5xFAD mice
exhibited 700 uniquely transcribed gene transcripts (Fig.
4A). Statistical analysis of the most differently expressed
genes across SPF and GF housing conditions and ABX
treatment in WT and 5xFAD mice revealed 1945 signifi-
cantly (adj. P < 0.0001) up- (red) and downregulated
(blue) genes in microglia (Fig. 4B, Additional file 9).
Among the differently expressed genes, we observed in
microglia from GF 5xFAD mice upregulated expression
of apolipoprotein E (Apoe) and Trem2, which are impli-
cated in Aβ detection and clearance [44, 60]. Moreover,
genes attributed to AD-associated microglial activation
[23, 27] including Axl, Cst7, Itgax (encoding CD11c),
Cd9 or Clec7a showed an overall increased and P2ry12
reduced expression in microglia from GF 5xFAD mice
(Fig. 4B). Subsequent IPA pathway analysis of differen-
tially expressed genes between microglia from WT and
(See figure on previous page.)
Fig. 3 Increased microglial phagocytosis in the hippocampus of 4 months old GF 5xFAD mice. (a) Representative immunofluorescence images of
TR+ (red) Aβ depositions and Iba1+ (green) microglia on coronal hippocampal sections of SPF, GF and ABX-treated 5xFAD mice and age-matched
WT controls. Nuclei were stained with DAPI (blue). Scale bar: 50 μm. Quantification of (b) Iba1+ parenchymal microglia in hippocampus of 5xFAD
and age-matched WT mice. Quantification of (c) TR+ plaque-associated microglia in 5xFAD mice. Each symbol represents one mouse. Data are
presented as mean ± s.e.m. Significant differences were determined by two-way ANOVA followed by Bonferroni’s post-hoc comparison test or by
one-way ANOVA followed by Tukey’s post-hoc comparison test (**P < 0.01, ***P < 0.001). Data are representative of four independent
experiments. (d) Gating of CD11b+methoxy-XO-4+ microglia from SPF, GF and ABX-treated 5xFAD mice and age-matched WT controls.
Representative dot plots are shown. (e) Representative cytometric graph of methoxy-X-O4+ labelled microglia from SPF (black line), GF (red line)
and ABX-treated (blue line) 5xFAD mice and respective WT controls (dashed lines). (f) Quantification of percentages of methoxy-X-O4+ labelled
microglia cells are depicted. Each symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by
two-way ANOVA followed by Bonferroni’s post-hoc comparison test (***P < 0.001). Data are representative of four independent experiments
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transgenic 5xFAD mice, housed under SPF or GF condi-
tions or after ABX treatment, revealed strongly atte-
nuated chemokine and mTOR signaling pathways in
microglia from GF and ABX-treated 5xFAD mice,
whereas neuroinflammation signaling pathways were
robustly diminished in microglia from GF 5xFAD mice,
leading to a strongly diminished repertoire of innate
immune response (Fig. 4C – E, Additional files 10, 11,
and 12). In contrast, microglia in ABX-treated 5xFAD
mice displayed increased activation z-score of interferon
signaling and Liver X Receptor (LXR) Retinoid X Recep-
tor (RXR) activation, which belong to the type II family
of nuclear receptors (NR). LXR and RXR signaling are
involved in a wide range of Aβ-related effects and are
also reported to promote anti-inflammatory effects in
microglia [64]. Remarkably, we detected predominantly
in microglia from GF 5xFAD mice robustly increased ex-
pression of genes attributed to oxidative phosphorylation
and mitochondrial dysfunction, while the induction of
genes linked to production of nitric oxide and reactive
oxygen species were reduced concomitantly (Fig. 4D,
Additional file 11). Further, we noticed an increased
expression of genes implicated in phagocytosis, such as
phagosome maturation and Cdc42 signaling [26], predo-
minantly in microglia from GF 5xFAD mice (Fig. 4C – F,
Additional files 10, 11, 12). In sum, the data is indicating
an altered activation state of microglia in GF 5xFAD mice,
while microglial phagocytosis is preferentially enhanced
under GF conditions.
Next, the differently expressed genes ApoE (Fig. 5A),
P2ry12 (Fig. 5B), Clec7a (Fig. 5C) and Itgax (Fig. 5D)
were verified on protein level. We noticed an increased
percentage of P2ry12dim/Iba1+ microglia in the hippo-
campus of GF 5xFAD mice (Fig. 5E & F), whereby TR+
plaque-associated microglia made up the majority of
total P2ry12dim/Iba1+ cells (Fig. 5G & H). Furthermore,
we confirmed increased ApoE and Clec7a expression in
hippocampal microglia from GF 5xFAD mice as evident
by increased percentages of ApoE+/Iba1+ (Fig. 5I – L)
and Clec7a+/Iba1+ plaque-associated and non-plaque-
associated microglia (Fig. 5M – P). Additionally, we
observed elevated expression of CD11c+ hippocampal
microglia from GF 5xFAD mice by flow cytometry (Fig.
5Q - S). Taken together, these findings demonstrate that
the previously described AD-linked activation signature
of microglia [23, 27] can be modulated by host
microbiota.
Microbiota-dependent enhanced microglial phagocytosis
of Aβ debris is age-related
Since it is well acknowledged that microglia become
exhausted during chronic exposure to Aβ debris in
mouse and human, we further examined whether micro-
glial clearance capacity is sustained in later AD disease
stage. First, we quantified Iba1+ parenchymal microglia
numbers in the hippocampi of 10 months old SPF, GF
and ABX 5xFAD mice and non-transgenic controls
(Fig. 6A & B). In contrast to 4 months old animals, dif-
ferences in microglial densities became indistinguishable
in the 5xFAD mice at 10 months of age. In addition, the
numbers of TR+ Aβ plaque-associated microglia were
similar in all three experimental groups (Fig. 6C). In
ex vivo flow cytometric analysis, the percentage of
methoxy-X-O4+ microglia showed no differences
(Fig. 6D – F, Suppl. Fig. 5B), thus demonstrating
the age-dependency of microbiota-controlled microglial
Aβ phagocytosis.
Discussion
Recent studies uncovered an essential contribution of
host microbiota during neurodegenerative diseases in-
cluding AD, however, the cellular and functional mecha-
nisms involved in the disease progression are not yet
understood. Here, we examined the influence of distinct
gut microbiota modulation strategies on microglia in the
context of AD. Colonized 5xFAD mice, housed under
SPF conditions, showed robust hippocampal Aβ path-
ology at early (4 months) and later disease stages (10
months), resulting thereby in disease stage-dependent
neuronal loss and hippocampal-associated memory
(See figure on previous page.)
Fig. 4 Altered microglial gene expression profiles in 5xFAD mice housed under GF conditions. (a) Venn diagram depicting the different regulated
and overlapping genes between FACS-isolated hippocampal microglia of SPF, GF and ABX-treated 5xFAD animals compared to respective non-
transgenic littermates of the same conditions (SPF/GF/ABX). (b) RNA-Seq analysis presenting mRNA expression profile of genes, whose expression
was either induced or reduced with an adjusted P value < 0.0001 in hippocampal microglia of SPF, GF and ABX-treated transgenic 5xFAD animals
and respective age-matched WT littermates. Representative genes are noted on the right. One column represents microglia from one individual
mouse. Three to five mice were investigated per condition. Color code presents z-score (red: upregulated, blue: downregulated). Ingenuity
pathway analysis (Qiagen) on differentially expressed genes in hippocampal microglia of SPF (c), GF (d) and ABX-treated (e) 5xFAD animals
compared to respective WT littermates of the same housing/treatment conditions (SPF/GF/ABX) based on an RNA-sequencing analysis. Diagram
depicts –log(p) value and predicted activation z-scores (red: increased activity, blue: reduced activity; grey: no predicted z-score available). (f)
Heatmap of differently expressed genes attributed to the pathway ‘phagosome maturation’ of hippocampal microglia from SPF, GF and ABX-
treated transgenic 5xFAD animals and respective age-matched WT littermates. Representative genes are noted on the bottom. One row
represents microglia from one individual mouse. Three to five mice were investigated per condition. Color code presents z-score (red:
upregulated, blue: downregulated)
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deficits. In contrast, constitutive (GF) or induced (ABX)
depletion of the host’s bacteria significantly alleviated Aβ
depositions and improved memory function. Import-
antly, constitutive and induced microbiota depletion
strategies resulted in activation of different Aβ clearing
mechanisms by the brain’s endogenous macrophages,
the microglia. In GF 5xFAD mice microglial Aβ uptake
was increased, while this was not the case upon
ABX-treatment of 5xFAD mice.
In general, commensal bacteria are a well-known fac-
tor in maintaining the host’s physiology [41], including
the innate and adaptive immune system in several tis-
sues and compartments [16]. Moreover, alterations in
the microbiota composition were linked to various hu-
man diseases, including several CNS disorders [7, 45, 55,
57, 58]. Their contribution to neurological health is
studied extensively, however it is partially challenging to
elucidate whether gut bacteria are a causative, propaga-
tive, or preventive factor during human health and dis-
ease. Nevertheless, growing evidence from preclinical
studies suggests that gut bacteria are an essential factor
contributing to CNS homeostasis and pathological con-
ditions [6, 14, 20, 42, 50]. We previously identified that
the commensal bacteria (presumably in the gut, due to
their highest abundance) maintain microglial maturation
and function in the CNS as evident by increased micro-
glial numbers, highly branched arborization and altered
gene expression patterns [12]. Interestingly, already dur-
ing embryonic brain development, microglia features are
essentially controlled by gut microbiota in a gender-
dependent manner [54].
In accordance with our own and previous observations
[18, 34] showing that host microbiota boost AD
pathology, emerging evidence implies that gut microbes
influence the pathogenesis of various neurodegenerative
CNS diseases [4, 13, 43]. However, it remained largely
unclear how this effect might be mediated. Harach and
colleagues reported, for instance, less Iba1+ microglia ac-
cumulation in AD 3.5 and 8months old mice under GF
conditions [18]. In contrast, by using the more aggressive
5xFAD mouse model, we found in the hippocampus of
GF housed transgenic mice an increased microglia density
at 4months of age. Of note, microglial numbers were
equalized at later stages of the disease at 10months of age.
These data indicate certain limitations related to the
different AD mouse models, as well as disease stage-
dependent divergences. Despite the usage of constitutive
gnotobiotic mouse models, which are highly artificial and
untranslatable to the human situation, long-term manipu-
lation of the gut microbiota with a cocktail of antibiotics
was described to result in decreased Aβ burden in
APPSWE/PS1ΔE9 AD model mice compared to non-treated
controls [34]. In line, we observed diminished Aβ deposi-
tions in ABX-treated 5xFAD mice at both, early (4
months) and late (10months) time points. This finding
suggests that the disease pathology can be alleviated even
at a progressed state, which could be useful for possible
late therapeutic interventions. Notably, in ABX-treated
5xFAD mice microglial density turned out to be on same
levels as observed in SPF housed transgenic controls, com-
plementary to unchanged microglia abundance during
homeostatic conditions in non-transgenic WT mice as
described before [12, 35, 54]. Importantly, we determined
that diminished Aβ burden in GF and ABX-treated 5xFAD
mice resulted at later stages in reduced neuronal loss and
in turn attenuated hippocampus-associated memory loss.
(See figure on previous page.)
Fig. 5 Altered expression of activation markers in hippocampal microglia from GF 5xFAD mice. Expression levels (counts per million) of (a) ApoE,
(b) P2ry12, (c) Clec7a and (d) Itgax in hippocampal microglia from SPF, GF and ABX-treated 5xFAD and age-matched WT mice, based on RNA-seq
data depicted in Fig. 4. Each symbol represents one mouse. Data are presented as mean ± s.e.m. (e) Representative immunofluorescence images
of Iba1+ (red), P2ry12+ (green) microglia and TR+ (white) Aβ on parasagittal hippocampal sections from SPF, GF and ABX-treated 5xFAD mice.
Nuclei were stained with DAPI (blue). Scale bar: 50 μm. White arrowheads indicate P2ry12dim/Iba1+ microglia and non-filled arrowheads show
P2ry12bright/Iba1+ microglia. Quantification of the percentage of (f) total parenchymal P2ry12dim/Iba1+ microglia (g) TR+ plaque-associated
P2ry12dim/Iba1+ microglia and (h) non-plaque-associated P2ry12dim/Iba1+ microglia in hippocampi of SPF, GF and ABX-treated 5xFAD mice. (i)
Representative immunofluorescence images of Iba1+ (red) ApoE+ (green) microglia and TR+ (white) Aβ on parasagittal hippocampal sections from
SPF, GF and ABX-treated 5xFAD mice. Nuclei were stained with DAPI (blue). Scale bar: 50 μm. White arrowheads indicate ApoE+/Iba1+ microglia
and non-filled arrowheads show ApoE−/Iba1+ microglia. Quantification of the percentage of (j) total parenchymal ApoE+/Iba1+ microglia (k) TR+
plaque-associated ApoE+/Iba1+ microglia and (l) non-plaque-associated ApoE+/Iba1+ microglia in hippocampus from SPF, GF and ABX-treated
5xFAD mice. (m) Representative immunofluorescence images of Iba1+ (red) Clec7a+ microglia (green) and TR+ (white) on coronal hippocampal
sections from SPF, GF and ABX-treated 5xFAD mice. Nuclei were stained with DAPI (blue). Scale bar: 50 μm. White arrowheads indicate Clec7a+/Iba1+
microglia and non-filled arrowheads show Clec7a−/Iba1+ microglia. Quantification of the percentage of (n) total parenchymal Clec7a+/Iba1+ microglia
(o) TR+ plaque-associated Clec7a+/Iba1+ microglia and (p) non-plaque-associated Clec7a+/Iba1+ microglia in hippocampus of SPF, GF and ABX-treated
5xFAD mice. Each symbol represents one mouse. At least three slides were examined per individual mouse. Data are presented as mean ± s.e.m.
Significant differences were determined by one-way ANOVA (*P < 0.05, **P < 0.01, ***P<0.001). Data are representative of two independent
experiments. (q) Representative cytometric graph of CD11c+ labelled microglia from SPF (black line), GF (red line) and ABX-treated (blue line) 5xFAD
mice and respective age-matched WT mice (dashed lines), compared to the isotype control (green line). In addition, quantifications of (r) percentages
and (s) geometric mean fluorescence intensities (gMFI) of CD11c+ microglia cells are depicted. Each symbol represents one mouse. Data are presented
as mean ± s.e.m. Significant differences were determined by two-way ANOVA followed by Bonferroni’s post-hoc comparison test or by one-way
ANOVA followed by Tukey’s post-hoc comparison test (*P<0.05, ***P < 0.001). Data are representative of three independent experiments
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How does the microbiota shape AD progression? Gen-
erally, the equilibrium between Aβ production and clear-
ance is regarded to be crucial for the Aβ burden in AD
brain [22]. In addition, impaired Aβ removal rather than
increased Aβ generation has been associated to the eti-
ology of sporadic AD in humans [32]. The production of
Aβ and APP processing was not altered in transgenic SPF,
GF and ABX-treated 5xFAD mice. However, GF 5xFAD
mice displayed an increased microglia accumulation close
to Aβ plaques, containing more Aβ debris intracellularly
compared to 4months old SPF and ABX-treated 5xFAD
mice, indicative of amplified phagocytic removal of Aβ.
Consistent with these observations, several molecules
regulating phagocytosis, such as Trem2, its adapter TYRO
protein tyrosine kinase binding protein (Tyrobp), comple-
ment receptors (e.g. complement C1q subcomponent sub-
unit B, C1qb) and Apoe were elevated in microglia from
GF 5xFAD mice. For the lipoproteins, and in particular
APOE, it is known that compact Aβ aggregates can be
phagocytosed more efficiently by microglia [52, 61]. Re-
markably, several genes (such as Clec7a, P2ry12, Itgax and
others), that have been recently associated to Aβ activated
microglia in AD mouse models [23, 27], as well as in hu-
man AD brains [56, 63], displayed altered expression in
microglia from GF 5xFAD mice, indicating a certain
microbiota-dependent influence on this microglial activa-
tion state. In addition, the microglial expression levels of
genes attributed to neuroinflammation and chemokine
signaling pathways were suppressed under GF conditions
and partially reduced after ABX treatment. Despite the
potential direct neurotoxic effects of such molecules, as it
was proposed in the context of Parkinson’s diseases [43],
cytokine expression is also implicated in affecting micro-
glial phagocytosis [3]. Of note, the observed elevated up-
take of Aβ depositions in GF 5xFAD mice was found to
be equalized at later stages of the disease. In contrast to
GF 5xFAD mice, acutely induced microbiota depletion by
ABX did not increase microglial uptake of Aβ at early or
late stages of the disease as compared to the SPF condi-
tion, suggesting other mechanisms of microbiota-driven
Aβ clearance.
It was further reported that conventionally housed
transgenic APPPS1 mice harbor alterations in gut
microbiota composition, including increased abundance
of e.g. Rikenellaceae, compared to the WT littermates. In
the 5xFAD mouse model, slight changes in the compos-
ition of the fecal microbiota were also described com-
promising Bacteroidetes and Firmicutes [5]. However, in
our 16S analysis of caecal contents we observed no major
alterations (with a q-value < 0.05). In a rather small study,
microbiota analysis of AD patients revealed declined mi-
crobial diversity as compared with control patients [58].
However, clinical implications of microbiota alterations
need to be further clarified in future studies.
In conclusion, we found that host microbiota con-
trolled microglia-mediated uptake of Aβ depositions in
the 5xFAD mouse model of AD, whereas we observed
different effects of constitutive (as in GF conditions) and
induced microbiota modulation (by ABX) as well as dis-
ease stage-dependent mechanisms. RNA-seq analysis of
FACS-purified hippocampal microglia uncovered distinct
microbiota-dependent gene expression patterns including
genes attributed to e.g. phagocytosis or complement
signaling. Further, we found genes ascribed to AD-linked
activation of microglia such as Cst7, Clec7a, Apoe or Itgax
being expressed in a microbiota-dependent manner.
These results provide deeper knowledge about the high
plasticity of the gut-microglia connection and treatment
of microglia-mediated CNS diseases.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-020-00988-5.
Additional file 1: Supplementary Fig. 1: Determination of intestinal
bacterial loads and microbiota composition analysis. (A) Photograph of
caeca from 4- and 10- months old SPF, GF and ABX-treated mice with
ruler for scaling and (B) relative caecal weight referred to the body
weight, and (C) absolute body weight. Each symbol represents one
mouse. Data are presented as mean ± s.e.m. Significant differences were
determined by one-way ANOVA followed by Tukey’s post-hoc compari-
son test (***P < 0.001). Data are representative of four independent exper-
iments. (D) Gating on DAPI−Syto9+ live bacteria of fecal samples from
SPF, GF and ABX-treated mice. Representative flow cytometric dot plots
are shown. (E) Percentages of live gram+ and gram- bacteria and (F)
quantification of live bacteria per mg fecal sample are depicted. Each
symbol represents one mouse. Data are presented as mean ± s.e.m. Sig-
nificant differences were determined by one-way ANOVA followed by
Tukey’s post-hoc comparison test (***P < 0.001). Data are representative
(See figure on previous page.)
Fig. 6 Equalized microglial Aβ phagocytosis in the hippocampus of aged 5xFAD mice. (a) Representative immunofluorescence images of TR (red)
and Iba1 (green) on coronal hippocampal sections from 10months old 5xFAD mice. Nuclei were stained with DAPI (blue). Scale bar: 50 μm.
Quantification of (b) Iba1+ parenchymal in hippocampus of 5xFAD and age-matched WT mice. Quantification of (c) TR+ plaque-associated
microglia in 5xFAD mice. Each symbol represents one mouse. Data are presented as mean ± s.e.m. Significant differences were determined by
two-way ANOVA followed by Bonferroni post-hoc comparison test (**P < 0.01, ***P < 0.001). (d) Gating of CD11b+methoxy-XO4+microglia from
SPF, GF and ABX-treated 5xFAD mice and age-matched WT controls. Representative flow cytometric dot plots are shown. (e) Representative
cytometric graph of methoxy-X-O4+ labelled microglia from SPF (black line), GF (red line) and ABX-treated (blue line) 5xFAD mice and respective
WT controls (dashed lines). (f) Quantification of percentages of methoxy-X-O4+ labelled microglia cells are depicted. Each symbol represents one
mouse. Data are presented as mean ± s.e.m.: No significant differences were detected by two-way ANOVA followed by Bonferroni post-hoc
comparison test. Data are representative of three independent experiments
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of four independent experiments. (G-J) Microbial species richness (alpha
diversity; Shannon and Simpson indices) in caecal contents from 4
months old SPF and ABX-treated 5xFAD mice and respective age-
matched WT controls. (K) Microbial clustering is shown based on Bray-
Curtis dissimilarity principal coordinate analysis (PCoA) metrics of caecal
contents from 4months old SPF and ABX-treated 5xFAD mice and re-
spective age-matched WT controls. Ellipsoids represent a 95% confidence
interval surrounding each group. Non-parametric analysis of variance
(Adonis) was used to test significant difference between groups on PCoA
plot; p < 0.001 for tested groups.
Additional file 2: Supplementary Fig. 2. Absence of host microbiota
reduces hippocampal Aβ depositions in 5xFAD mice. (A) Representative
immunofluorescence images of 6E10+ (red) compact and diffuse Aβ
plaques in the hippocampus of 4 months old SPF, GF and ABX-treated
5xFAD mice. Nuclei were stained with DAPI (blue). Overview of hippo-
campus and magnification of subiculum (dashed line) are shown. Scale
bars represent 300 μm (overview) and 50 μm (insert). (B) Quantification of
the number of 6E10+ Aβ-plaques per mm2, (C) percentage of 6E10+ area
and (D) average 6E10+ plaque size (μm2) in coronal hippocampal sections
of SPF, GF and ABX-treated 5xFAD mice. Each symbol represents one
mouse. Data are presented as mean ± s.e.m. Significant differences were
determined by one-way ANOVA followed by Tukey’s post-hoc compari-
son test (***P < 0.001). Data are representative of four independent exper-
iments. (E) Insoluble Aβ42/Aβ40 and (F) soluble Aβ42/Aβ40 ratio of
hippocampal brain extracts from 4months old SPF, GF and ABX-treated
5xFAD mice. ELISA for (G) insoluble Aβ42, (H) insoluble Aβ40, (I) soluble
Aβ42, (J) soluble Aβ40, (K) ratio of insoluble Aβ42/ Aβ40 and ratio of sol-
uble Aβ42/ Aβ40 of hippocampal brain extracts of 10 months old SPF, GF
and ABX-treated 5xFAD mice. Each symbol represents one mouse. Data
are presented as mean ± s.e.m. Significant differences were determined
by one-way ANOVA followed by Tukey’s post-hoc comparison test (**P <
0.01, ***P < 0.001). Data are representative of two independent experi-
ments. (L) Representative immunoblots of hippocampal brain homoge-
nates of 10 months old SPF, GF and ABX-treated 5xFAD mice against
human APP-FL, CTF-β, CTF-α, BACE1, ADAM10, PS1, PS2, PEN2, Nicastrin,
and Aβ (6E10). β-Actin was used as loading control. Each lane represents
one mouse. Quantification of (M) APP-FL, (N), CTF-β, (O) CTF-α, (P) BACE1,
(Q) ADAM10, (R) PS1, (S) PS2, (T) PEN2, (U) Nicastrin, and (V) Aβ (6E10)
protein levels normalized to β-Actin. Each symbol represents one mouse.
Data are presented as mean ± s.e.m. Significant differences were deter-
mined by one-way ANOVA followed by Tukey’s post-hoc comparison test
(*P < 0.05, **P < 0.01). Homogenates of three mice per group were used.
(W) Representative immunofluorescence images of 6E10+ compact and
diffuse Aβ plaques in the hippocampus of 10 months old 5xFAD mice.
Nuclei were stained with DAPI (blue). Overview of hippocampus and
magnification of subiculum (dashed line) are shown. Scale bars represent
300 μm (overview) and 50 μm (insert). (X) Quantification of the number
of 6E10+ Aβ-plaques per area (mm2), (Y) percentage of 6E10+ area and
(Z) average 6E10+ plaque size (μm2). Each symbol represents one mouse.
Data are presented as mean ± s.e.m. Significant differences were deter-
mined by one-way ANOVA followed by Tukey’s post-hoc comparison test
(*P < 0.05, ***P < 0.001). Data are representative of three independent
experiments.
Additional file 3: Supplementary Fig. 3. Memory function in 4
months old SPF, GF and ABX-treated 5xFAD mice. (A) Ratio of right ver-
sus left arm entries in the T-maze spontaneous alternation test of 10
months old SPF and GF or (B) SPF and ABX-treated 5xFAD and age-
matched WT mice. (C-F) T-maze of 4 months old SPF and GF mice or
(G-J) SPF and ABX-treated 5xFAD, as well as respective age-matched WT
mice. (K-M) Novel object recognition task of 4 months old SPF and GF
5xFAD, as well as age-matched WT mice or (N-P) SPF and ABX-treated
5xFAD, as well as WT mice. Each symbol represents one mouse. Data are
presented as mean ± s.e.m. Significant differences were determined by
two-way ANOVA followed by Bonferroni’s post-hoc comparison test
(*P < 0.05, **P < 0.01, ***P < 0.001). Data are representative of three inde-
pendent experiments. (Q) Representative immunofluorescence images of
NeuN+ neurons (green) and TR+ (red) compact Aβ-plaques in the subicu-
lum of the hippocampus of 4 months old SPF, GF and ABX-treated 5xFAD
and respective age-matched WT mice. Nuclei were stained with DAPI
(blue). Overview of hippocampus and magnification of subiculum
(dashed line) are shown. Scale bars represent 200 μm (overview) and
50 μm (insert). (R) Quantification of the number of NeuN+ neurons per
mm2 in the subiculum (Sub) of sagittal hippocampal sections from SPF,
GF and ABX-treated 5xFAD and WT mice. Each symbol represents one
mouse. Data are presented as mean ± s.e.m. No significant differences
were determined by two-way ANOVA followed by Bonferroni’s post-hoc
comparison test. Data are representative of two independent
experiments.
Additional file 4: Supplementary Fig. 4. Microglial density in
hippocampus of 4 months old 5xFAD mice. (A) Representative
immunofluorescence images of Iba1+ (green) microglia on coronal
hippocampal sections of 4 months old SPF, GF and ABX-treated WT mice.
Nuclei were stained with DAPI (blue). Scale bar: 50 μm. (B) Representative
immunofluorescence images of 6E10 (red) and Iba1 (green) on coronal
hippocampal sections of 4 months old 5xFAD mice. Nuclei were stained
with DAPI (blue). Scale bar: 50 μm. (C) Quantification of 6E10+ plaque-
associated microglia. Each symbol represents one mouse. Data are repre-
sented as means ± s.e.m. Significant differences were determined by
one-way ANOVA followed by Tukey’s post-hoc comparison test (**P < 0.01,
***P < 0.001). Data are representative of two independent experiments.
Additional file 5: Supplementary Fig. 5. Gating of hippocampal
microglia in 5xFAD mice and non-transgenic controls. Gating of
CD11b+CD45low microglia from (A) 4 months old or (B) 10 months old
SPF, GF and ABX-treated 5xFAD mice and age-matched WT controls.
Representative dot plots are shown.
Additional file 6. Table 1. Maaslin Analysis Output (H2O Group for
Genotype Comparison).
Additional file 7. Table 2. Maaslin Analysis Output (ABX Groups for
Genotype Comparison).
Additional file 8. Table 3. Venn-diagram related genes.
Additional file 9. Table 4. List of DEG.
Additional file 10. Table 5. Pathway analysis SPF FAD vs WT.
Additional file 11. Table 6. Pathway analysis GF FAD vs WT.
Additional file 12. Table 7. Pathway analysis ABX FAD vs WT.
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